Synlico Inc. Information

Aerospace and automotive engineers do not commit to building a new engine, aircraft, or vehicle until simulation has tested its performance, structural integrity, and potential failure modes across realistic operating conditions. Drug developers still lack an equivalent platform for determining whether a target or mechanism will behave as intended across the tissues, cell states, and biological diversity of real patients before entering clinical trials. Synlico's SynCausal™ is built to fill this gap. SynCausal™ represents biology through causal graphs that link upstream genes and pathways to downstream cell states and phenotypes, enabling intervention effects to be simulated, traced, and compared. It operates one level upstream of medicinal chemistry and modality engineering: determining which biological intervention is worth pursuing, why it may work, and in which patient contexts the hypothesis is most credible. Application SynCausal™ seeks to build a computational layer that represents disease in its native patient, cellular, and tissue context, then uses virtual biological interventions to discover and prioritize disease-driving targets, uncover novel mechanisms, and evaluate how those mechanisms may respond to therapeutic modulation.